TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01184235
Drug: Pharmacological Intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will include those anticipating or receiving any pharmacological intervention
Study: NCT01149525
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2g oral solution , twice per day (morning/evening), during 3 months
Study: NCT00310089
Drug: cediranib maleate
Normalized name: maleate
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00676234
Drug: epoetinum
Normalized name: Epoetinum zeta
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
Study: NCT00310089
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00880048
Drug: orvepitant
Normalized name: Orvepitant
DrugBank: Orvepitant (DB12427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neurokinin-1 antagonist
Study: NCT02325440
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fingolimod: 0.5 mg p.o. (o.i.d)
Study: NCT02325440
Drug: Natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab: 300 mg i.v. (once at baseline);
Study: NCT00367991
Drug: Recombinant human erythropoietin alfa (drug)
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
Study: NCT02505802
Drug: BoNT-A injection
Normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
Study: NCT01637662
Drug: Natriuretic peptides
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. infusion between 0.2-3 microgram over 20 minutes
Study: NCT03449719
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
Study: NCT00717626
Drug: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
DrugBank: Humate-P (DB17966)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
Study: NCT03897348
Drug: Lacosamide 100 mg
Normalized name: lacosamide 100 MG
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral medication
Study: NCT03897348
Drug: Lacosamide 200 mg
Normalized name: lacosamide 200 MG
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral medication
Study: NCT01097343
Drug: clopidogrel 75 mg
Normalized name: clopidogrel 75 MG
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg once daily
Study: NCT01097343
Drug: Clopidogrel 150 mg
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: clopidogrel 150 mg
Study: NCT02566707
Drug: Atazanavir
Normalized name: Atazanavir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HIV therapy will be adapted: atazanavir 400mg QD
Study: NCT02566707
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HIV therapy will be adapted: dolutegravir 50mg QD
Study: NCT02566707
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HIV therapy will be adapted: lamivudine 300mg QD
Study: NCT01556971
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
Study: NCT01556971
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
Study: NCT00165451
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration once daily at night starting at 3mg/Kg for 6 months.
Study: NCT00165451
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
Study: NCT00319566
Drug: Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03900637
Drug: Leuprorelin acetate
Normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
Study: NCT03900637
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
Study: NCT01161498
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by intravenous infusion
Study: NCT03462589
Drug: SY-008
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
Study: NCT00664430
Drug: Calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
Study: NCT00664430
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
Study: NCT05437783
Drug: Azithromycin Dihydrate
Normalized name: Azithromycin Dihydrate
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
Study: NCT02784171
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02784171
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02784171
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00407641
Drug: Tinzaparin administration
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive tinzaparin during the HD session
Study: NCT01025232
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal Injection of 2.0mg formulation
Study: NCT03052361
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to this arm will receive ondansetron in the ED triage.
Study: NCT00145041
Drug: Vincristine Sulfate Liposomes Injection
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
Study: NCT00253058
Drug: Cetirizine Dry Syrup
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02876484
Drug: Colesevelam
Normalized name: Colesevelam
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02135341
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
Study: NCT02135341
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
Study: NCT01679340
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
Study: NCT01679340
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
Study: NCT01679340
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
Study: NCT02709863
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-1.5 MAC, inhalation route, during operation
Study: NCT02709863
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-1.5 MAC, inhalation route, during operation
Study: NCT02709863
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-10 mg/kg/h, iv infusion, during operation
Study: NCT01697319
Drug: BMN 110
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
Study: NCT00032799
Drug: natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03398837
Drug: Lenabasum 5 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive lenabasum 5 mg twice daily.
Study: NCT03398837
Drug: Lenabasum 20 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive lenabasum 20 mg twice daily.
Study: NCT04402320
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: reconnected to mechanical ventilation before extubation for one hour with sedation with midazolam 3-5 milligram/hour intravenous infusion to achieve score 0 or -1on Richmond Agitation - Sedation Scale (RASS). 20 minutes before the end of this hour midazolam infusion discontinued and patients awaked. Patient put on mechanical ventilation (MV) with the following parameters, FIO2 40%, pressure SIMV mode, PEEP 8 cmH2O, Pressure support 15 cmH2O, Respiratory rate 14/min, Peak inspiratory pressure (PIP) of 35 cmH2O. Then patients extubated and followed our previous protocol without the use
Study: NCT00628719
Drug: Liposomal Amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single dose of 10 mg/kg of liposomal amphotericin B
Study: NCT00628719
Drug: amphotericin B deoxycholate
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
Study: NCT00188136
Drug: Melphalan, ATG, Fludarabine
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: allo Tx during aplasia
Study: NCT03356444
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
Study: NCT00373880
Drug: Aripiprazole + Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
Study: NCT00373880
Drug: Placebo + Cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
Study: NCT00302770
Drug: quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04023344
Drug: Humalog Mix25
Normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study: NCT04023344
Drug: Insulin Lispro Biphasic 25
Normalized name: insulin lispro 25 UNT/ML
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study: NCT03356444
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment
Study: NCT00553189
Drug: ABT-888
Normalized name: ABT-925
DrugBank: ABT-288 (DB15192)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00553189
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00466076
Drug: Copaxone (Glatiramer acetate)
Normalized name: glatiramer acetate Prefilled Syringe [Copaxone]
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01332383
Drug: Naratriptan
Normalized name: Naratriptan
DrugBank: Naratriptan (DB00952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01594619
Drug: Naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral 25mg tablet
Study: NCT01594619
Drug: Diltiazem XR
Normalized name: diltiazem Extended Release Oral Capsule
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 240mg tablet
Study: NCT01385657
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A total of 4 doses were administered.
Study: NCT01928927
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received Telmisartan 40 mg daily during weeks 0-4 followed by telmisartan 80 mg daily during weeks 5-48.
Study: NCT00042224
Drug: Clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with psychotic symptoms will receive clozapine
Study: NCT00028093
Drug: Peginterferon alfa-2a with Ribavirin
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients \>=75 kg) for 48 weeks
Study: NCT00028093
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
Study: NCT00688519
Drug: U0267
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
Study: NCT00622830
Drug: SB-480848 (Darapladib)
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05148689
Drug: Oxymetazoline hydrochloride Cream, 1%
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream
Study: NCT03906539
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10 mg per day
Study: NCT03009799
Drug: Iota-Carrageenan
Normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
Study: NCT03009799
Drug: Carmellose
Normalized name: Carmellose
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
Study: NCT00332436
Drug: brimonidine/timolol fixed combination
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01698723
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02845050
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy
Study: NCT00211328
Drug: anecortave acetate
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02845050
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy
Study: NCT01611662
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01611662
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04007367
Drug: SAGE-217
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 capsule
Study: NCT00702936
Drug: TELMISARTAN
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg daily
Study: NCT00702936
Drug: RAMIPRIL
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg daily
Study: NCT02171442
Drug: BIBR 1048 Oral Solution
Normalized name: bibrocathol
DrugBank: Bibrocathol (DB13818)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg free base, 2.8 MBq (76 µCi)
Study: NCT02557737
Drug: Botulinum Toxin Type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
Study: NCT02866227
Drug: TOL-463
Normalized name: TOL-101
DrugBank: TOL-101 (DB16980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL-463 vaginal gel
Study: NCT02866227
Drug: TOL-463
Normalized name: TOL-101
DrugBank: TOL-101 (DB16980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOL-463 vaginal insert
Study: NCT01706120
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
Study: NCT01706120
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
Study: NCT01706120
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: • Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
Study: NCT01764022
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).